Page last updated: 2024-12-08

1',3'-dimethylspiro[1H-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1',3'-dimethylspiro[1H-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione, also known as **Spiroindolone**, is a synthetic compound that has gained significant attention in research due to its potential therapeutic applications.

**Structure and Properties:**

* **Structure:** Spiroindolone is a heterocyclic compound with a spirocyclic structure, containing a fused indole ring and a dihydropurine ring. The '1' and '3' positions of the indole ring and the '2' position of the dihydropurine ring are connected by a carbonyl group.
* **Properties:** Spiroindolone is a solid compound with a high melting point. It is poorly soluble in water but soluble in organic solvents.

**Research Significance:**

Spiroindolone has been investigated for its potential in several areas of research, including:

* **Anti-cancer Activity:** Studies have shown that spiroindolone derivatives exhibit potent anti-cancer activity against various tumor cell lines. They are thought to work by targeting specific signaling pathways and inhibiting cell proliferation.
* **Neuroprotective Effects:** Spiroindolone has been found to protect against neuronal damage caused by oxidative stress and inflammation. This makes it a promising candidate for the treatment of neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Anti-inflammatory Activity:** Spiroindolone has demonstrated anti-inflammatory properties, suggesting its potential as a therapeutic agent for inflammatory conditions.
* **Antiviral Activity:** Some spiroindolone derivatives have shown activity against viruses, including HIV.
* **Immunosuppressant Activity:** Spiroindolone has been reported to have immunosuppressant effects, which could have applications in organ transplantation or autoimmune disorders.

**Current Research Focus:**

Ongoing research on spiroindolone focuses on:

* **Synthesizing new derivatives:** Researchers are actively developing new spiroindolone analogues with enhanced activity and selectivity.
* **Understanding mechanism of action:** Studying the molecular mechanisms by which spiroindolone exerts its effects is crucial for optimizing its therapeutic applications.
* **Preclinical and clinical trials:** Promising spiroindolone derivatives are being evaluated in preclinical animal studies and early clinical trials to assess their safety and efficacy in human patients.

**Conclusion:**

1',3'-dimethylspiro[1H-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione (Spiroindolone) is a versatile compound with promising therapeutic potential in various areas of medicine. Its ability to target multiple cellular pathways and its diverse pharmacological activities make it a subject of intense research interest. Further investigation and clinical trials are needed to fully explore its therapeutic potential and develop safe and effective drugs based on this scaffold.

Cross-References

ID SourceID
PubMed CID272594
CHEMBL ID1527587
CHEBI ID121982

Synonyms (15)

Synonym
1',3'-dimethyl-7',9'-dihydrospiro[indole-3,8'-purine]-2,2',6'(1h,1'h,3'h)-trione
nsc-117197
mls000737483 ,
nsc117197
21943-52-2
smr000528533
CHEBI:121982
1',3'-dimethylspiro[1h-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione
HMS2885L06 ,
CHEMBL1527587
Q27210606
DTXSID40297659
DTXSID50944662
2-hydroxy-1',3'-dimethyl-7',9'-dihydrospiro[indole-3,8'-purine]-2',6'(1'h,3'h)-dione
1',3'-dimethyl-7',9'-dihydrospiro[indoline-3,8'-purine]-2,2',6'(1'h,3'h)-trione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.58490.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
acid sphingomyelinaseHomo sapiens (human)Potency7.943314.125424.061339.8107AID504937
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency31.62280.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency31.62280.01268.156944.6684AID2101
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.16230.036619.637650.1187AID1466; AID2242
importin subunit beta-1 isoform 1Homo sapiens (human)Potency100.00005.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency100.00005.804836.130665.1308AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency8.91250.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency31.62280.425612.059128.1838AID504891
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency10.00000.00419.962528.1838AID2675
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.16233.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.16233.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]